In kidney cancer, benign oncocytomas are TXNIP-positive in most cases (90.2%), while TXNIP expression got lost in malignant renal cell carcinomas (ranging from 29.8 to 42.1%, Figure 2d). Here, TXNIP is linked to renal cell adenocarcinoma.